The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss for the period | -954,059 | -197,929 |
| Amortization of right-of-use assets | 15,439 | 29,663 |
| Interest expense | - | -4,447 |
| Prepaid expenses | 8,580,932 | 5,110 |
| Lease liabilities | -15,302 | -29,048 |
| Accounts payable | 114,220 | -4,731 |
| Interest payable | - | 4,447 |
| Accrued expenses | 5,294 | -4,553 |
| Other current assets | - | 228,321 |
| Net cash provided by (used in) operating activities | -9,187,019 | -440,029 |
| Issuance of common stock | - | 0 |
| Issuance of preferred stock | - | 0 |
| Proceeds from issuance of common stock, net of underwriting costs | 15,655,192 | - |
| Loan from shareholders | - | 400,000 |
| Payment offering costs | 346,497 | - |
| Net cash provided by financing activities | 14,908,695 | 400,000 |
| Net increase (decrease) in cash | 5,681,646 | - |
| Cash and cash equivalents at beginning of period | 148,891 | - |
| Net increase (decrease) in cash | - | -40,029 |
| Cash and cash equivalents at end of period | 5,830,537 | - |
Curanex Pharmaceuticals Inc (CURX)
Curanex Pharmaceuticals Inc (CURX)